Levocetirizine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H25ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6U5EA9RT2O, chemically known as acetic acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- but generally known as levocetirizine, which bears US NIH Compound Identifier 1549000. European Medicines Agency schedules Levocetirizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08467MIG. The term LEVOCETIRIZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). World Health Organization schedules levocetirizine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule levocetirizine under HS 29335995 and SITC 51576. As of Q4 2014, LEVOCETIRIZINE remains the US FDA Preferred Term for this commodity. Levocetirizine bears US NLM identifiers UMLS ID C1174893 and NCI Concept Code C66008. SMILES: CLC1CCC(C(N2CCN(CC2)CCOCC(=O)O)C2CCCCC2)CC1.